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ABSTRACT

Yermakoff, Jeannee Karen. Ph.D., University of Rhode Island, 1980.
Characterization of the Fibrotic Lesion in Dibutyltin-induced Experimental Liver Injury. Major Professor: Dr. George C. Fuller.
Administration of di-n-butyltin dichloride (DBT) by oral intubation
has

been shown to produce hepatic fibrosis in rats.

Unlike post-necro-

tic experimental fibrosis, DBT-induced hepatic fibrosis progresses from
inflanunation and biliary injury.

The relationship of histological

changes to various parameters of collagen synthesis and liver injury
were investigated.

In vitro collagen synthesis was determined by incu-

bation of liver biopsies with labelled praline and subsequent digestion
with protease-free collagenase.

Prolyl hydroxylase activity in liver

homogenates was taken as a second parameter reflecting the rate of
collagen synthesis.

DBT administration (20 mg/kg/day, p.o.) produced

a progressive increase in both in vitro collagen synthesis and prolyl
hydroxylase activity from 0 to 4 days.

The increases in these two para-

meters were significantly correlated and both accompanied the appearance
of inflammatory cells in portal tracts and bile duct proliferation.
Serum alanine transaminase activity was increased after 4 days of DBT
administration.

DBT administration (20 mg/kg, q.o.d., p.o.) for 12 days

produced increased prolyl hydroxylase activity, an increase in the percent of in vitro collagen synthesis, and the accumulation of hydroxypraline in the liver.

These biochemical changes were associated with

fibrosis, bile duct proliferation and extensive inflammation in the
portal tracts.

Alanine transaminase and alkaline phosphatase activities

in serum were unchanged after 12 days of DBT treatment.

Rats 4 weeks

of age at the start of treatment were relatively resistant to the
effects of DBT (20 mg/kg, q.o.d., p.o.) administered for 12 days.
Prolyl hydroxylase activity in these 4-week old rats was 125% of control
compared to 150% and 215% in the 9- and 14-week old groups, respectively.
Leucocytosis and weight loss usually associated with DBT-induced liver
injury were absent in these younger rats and histology was similar to
that of control animals.
rats.

Thymus atrophy was observed in the 4-week old

Investigation of lymphocyte-mediated cytotoxicity, delayed type

hypersensitivity, and immunofluorescence in rats 9 weeks of age at the
start of treatment failed to reveal an immunologic reaction against DBT
or liver.

The relationship of differences in hepatic microsomal meta-

bolism to the age-related phenomena was investigated using an inhibitor
of microsomal enzymes, SKF 525A.

Administration of SKF 525A (50 mg/kg,

b.i.d., p.o.) concomitantly with DBT (20 mg/kg/day, p.o.) resulted in
an interaction between these two compounds with respect to their effect
on prolyl hydroxylase activity.

The elevation in serum alanine trans-

aminase activity seen with DBT treatment alone after 4 days was completely prevented by the simultaneous administration of SKF 525A.
Periportal inflammation and biliary chan?es were absent in rats receiving DBT and SKF 525A.
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INTRODUCTION

The toxicity of organotin compounds became apparent in the mid
1950s following their unfounded use as therapeutic agents and ensuing
disastrous results.

The toxicology of organotin derivatives remains of

interest today as a result of their continued industrial uses.

Alkyl-

tins are widely used as stabilizers and catalysts by the plastics indus(~iver,

tries

1973) and as biocidal agents (McCollister and Schober,

1975).
The hepatic and biliary manifestations of dialkyltin toxicity in
rats has been known for some time (Barnes and McGee, 1958; Barnes and
Stoner, 1958; Gaunt et al.,

1968) ~

More recently, toxicity to thymus-

dependent lymphocytes in vitro and impairment of cell-mediated immune
functions in rats have been attributed to the dialkyltins (Seinen et
al., 1977a and 1977b).
Administration of di-n-butyltin dichloride (DBT) to rats has been
shown to produce an experimental model of hepatic fibrosis which is
associated with periportal inflammation and bile duct proliferation
(Yermakoff, 1978).

This investigation attempts to further characterize

the fibrotic hepatic lesion induced by this organotin compound.

The

relationship of DBT-induced changes in biochemical parameters of hepatic collagen synthesis and liver injury to the associated histopathology is examined with special emphasis on hepatic inflannnation.

1

2
A possible connection between this compound's hepatotoxic and immunotoxic properties is investigated.

The role of metabolism in DBT-

induced liver injury is also examined.

LITERATURE SURVEY

Collagen Biosynthesis
Collagen is the most ubiquitous protein in higher vertebrates.
Its

pr~sence

in the extracellular matrix, as rigid fibers consisting of

cross-linked collagen molecules, provides structural support in these
organisms.

Collagen molecules each consist of three alpha (a) chains,

left-handed helices, coiled into a unique right-handed triple helix.
At least five, and possibly more, types of collagen molecules have
been identified; these have been recently reviewed by Eyre (1980).
Intersitial collagens include types I and III.

Type ·I, found primarily

in skin, bone, and tendon, consists of two al chains and one a2 chain,
which are distinguishable by their separation on carboxymethylcellulose
colunms.

It is represented by the molecular formula [al{I)] az.
2

Types

II and III each consist of three identical al chains, with each type
differing slightly in amino acid composition.

Type II ([al(II)] ) is
3

found in cartilage and type III {[al(III)] ) in fetal tissue, uterus
3
and blood vessels.

Collagen of the basal lamina, basement membrane

collagen, is distinct from the previous three in its lack of fibrillar
structure.

Its precise molecular structure, originally thought to be

[al(IV)] , is under question.
3

Recently,

collage~

aA and aB chains have

been isolated . from various sources including human placenta, infant
cartilage (Rhodes and Miller, 1978), and lung parenchyma (Madri and
Furthmayr, 1979).

Their molecular formula(s) is uncertain.
3

4
Collagen is unique among proteins in the extent of its post-translational modifications.

Its biosynthesis consists of the assembly of a

proline-, lysine-, and glycine-rich polypeptide precursor, procollagen.
Hydroxylation of both proline (Prockop and Juva, 1965) and lysine
(Sinex et al., 1959) has been shown to occur subsequent to the incorporation of these amino acids into procollagen chains.

Intracellular

hydroxylation of collagen precursor has been shown to be requisite for
stable helix formation and secretion (Uitto and Prockop, 1974).

Follow-

ing hydroxylation of lysine, some of these residues are glycosylated to
galactosylhydroxylysine and glucosylgalactosylhydroxylysine (Spiro and
Spiro, 197la and 197lb).

Cellular processing of procollagen a chains

also includes interchain disulfide-bond linkage in nonhelical regions
of the molecule which is essential for triple-helix formation
(Speakman, 1971).
Following the secretion of procollagen, terminal nonhelical
regions are enzymatically removed (Tuderman et al., 1978; Davidson et
al., 1977).

Collagen cross linking occurs through additional extra-

cellular processing by the enzyme lysyl oxidase, which oxidatively deaminates specific lysine residues leaving aldehyde moieties.

These, in

turn, form cross links through condensation reactions (Siegal et al.,
1970).

In mammals, collagen is cleaved by collagenases to form two fragments, referred to as TCA and TCB, which are then degraded further by
relatively nonspecific proteases (Perez-Tamayo, 1978).

The enzyme pro-

bably exists in vivo in three forms: latent enzyme, free enzyme, and
enzyme bound to collagen.

5

Inflannnatory and Immunologic Processes
in Hepatic Fibrosis
It is well-established that the amount of collagen is increased
in liver disease resulting from exposure to various xenobiotics.

Such

fibrosis is associated with chronic alcoholism (Chen and Leevy, 1975;
Mann et al., 1979), exposure to environmental toxicants (Popper et al.,
1979), and certain therapeutic agents (Maddrey and Boitnott, 1979).
Xenobiotic-induced liver disease has been broadly classified into three
categories: cytotoxic, which include steatosis; cholestatic; and mixed
cytotoxic and cholestatic (Zinnnerman, 1978).
Regardless of etiology and histologic classification, all types of
chemical-induced hepatic injury share the possibility of progression to
fibrosis via one or a combination of the following processes.

The first

of these is the stimulation of collagen production by or increased proliferation of collagen-producing cells.

The second is the increased

extracellular maturation of collagen fibrils from secreted procollagen.
A decrease in collagenolytic processes may result in fibrosis.
Finally, a minor contribution to fibrosis may result from the collapse
and aggregation of preformed collagen fibers.
The mechanism of chemical-induced hepatic fibrogenesis has been
extensively investigated utilizing models of fibrosis induced by compounds such as carbon tetrachloride (Aterman, 1954; McLeon et al.,
1969; McGee et al., 1973) and dimethylnitrosamine (Madden et al., 1970),
which are predominately post-necrotic.

These studies have led to the

hypothesis that hepatocytes, upon their death, release products to

6
stimulate fibrogenesis (Popper, 1975).

However feasible, the applica-

tion of this hypothesis -to most types of xenobiotic-induced liver fibresis in humans is somewhat untenable.

Specifically, alcoholic and drug-

induced fibrosis in humans is connnonly associated with an imflannnatory
and/or innnunologic component not seen in these post-necrotic models of
hepatic fibrosis.
Inflannnatory and/or innnunologic processesa have been associated
with a broad range of fibrotic diseases.

Fibrogenesis in inflammatory/

innnunologic disease states has been attributed to fibroblast proliferation (Wahl et al., 1978), increased collagen synthesis by fibroblasts
(Johnson and Ziff, 1976), and fibroblast chemotaxis (Posthelwaite et
al., 1976) in response to factors derived from innnunocompetent cells.
Recently, evidence has been accumulating that immunocompetent
cells and products released by these cells play a substantial role in
the initiation and/or perpetuation of hepatic fibrogenesis.

In both

hepatitis B (HB) antigen-negative and HB antigen-positive hepatitis,
autoimmune aggression has been implicated as a means of perpetuating
liver cell injury (Paronetto and Popper, 1976).

In a recent review,

Buschenfelde et al. (1979) suggested that the HB virus by itself is not
injurious to cells and that the host innnune response is responsible for
the tissue damage in acute and chronic HB virus-induced hepatitis.

In

HB antigen-negative hepatitis, antibody against native liver membrane
antigens has been detected, which corresponds with histologic evidence
~nless otherwise specified, throughout this text these processes
are considered together since it is often difficult to clearly distinguish one from the other. Inflannnation may be a component and/or consequence of an immune response (Voisen, 1977).

7

of inflammation and continuing necrosis (Hopf et al., 1976).

A cell-

mediated immune response to collagen has been suggested to initiate the
progression of hepatitis to cirrhosis (Chen et al., 1978).

In primary

biliary cirrhosis as many as one-third of patients have been estimated
to possess antiductular cell antibodies and 80% antimitochondrial antibodies (Schaffner, 1979).

Finally, experimental liver injury has been

produced in rats by immunization with heterologous sera lParanetto and
Popper, 1966).
Inflammatory and/or immunologic processes are part ot the pathogenetic scenario of drug- and chemical-induced hepatic fibrosis in many
instances.

However, it is difficult to determine the relative contri-

bution of these processes to the etiology and perpetuation of such
liver disease.

The primary reaction may be an inflammatory and/or

immunologic response to the drug and/or drug products, a toxic reaction
to the compound and/or its metabolites, or any combination of these
phenomena (Maddrey and Boitnott, 1979).
Understanding of immunologic reactivity to drugs and other chemicals, or drug allergy, has been advanced by recent work with penicillamine.

This drug has been shown to react with compounds containing

disulfide groups to form disulfides which are at least partially responsible for the immune response resulting from penicillamine administration (Dewdney, 1979).

Such work has suggested that the potential

for drug allergy is a function of a compound's ability to form covalent
bonds with macromolecules at physiological conditions (McGovern et al.,
1970; Dewdney, 1979).

The knowledge of the formation of haptenic

determinants has been of some predictive value in drug allergy, but

8

unequivocal demonstration of cause and effect has been hampered by the
diversity of immunologic responses and methodological inadequacies
(DeWeck, 1979).
The association of drug with disease in suspected hepatic manifestations of drug allergy has been even more elusive.

When immune

reactivity to a drug can be demonstrated, it does not necessarily imply
that such reactivity is the cause of liver injury.

Consequently, the

nature of immunologic reactions involved in hepatic drug allergy have
not been clearly identified (Girard, 1974).
Hepatic manifestations of drug and chemical allergy are commonly
diagnosed by indirect means such as recurrence of symptoms with repeated
exposure.

The major problem resulting from this practice is the identi-

fication of host idiosyncracy as drug allergy.
evidence has been convincing.

Nonetheless, much of the

Halothane produces jaundice in a small

number of patients (Zimmerman, 1972), and, in a remarkably thorough
case study, repeated episodes of hepatitis have been correlated with
exposure to halothane in an anesthetist (Klatskin and Kimberg, 1969).
Primary biliary cirrhosis, a disease in which the majority of patients
demonstrate autoantibodies, is often associated with a history of drug
allergy (Paronetto et al., 1964a); phenothiazines and androgenic steroids produce liver injury similar to that seen in primary biliary cirrhosis

(Dickson~

al., 1979).

The environmental toxicant, 2,3,7,8-

'
tetrachlorodibenzo-p-dioxin (TCDD),
produces liver injury (Neal et

al., 1979) and is suspected to be immunogenic (Luster et al., 1979) in
mice.

However, a connection between chemical-induced experimental liver

injury and antigenicity of such toxicants has not been established.
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Drugs and other chemicals may also produce a destructive cholangitis in which inflammatory processes occur in the liver in the absence
of evidence of immunologic phenomena (Zimmerman, 1978).

Such inflamma-

tion has been suggested to be a reaction to cholestasis (Popper and
Schaffner, 1970) although cholestasis is not always the primary event
(Krstulovic, 1968).

The distinction between such inflammatory reactions

and immunologic processes is not well defined.

In fact, it has been

suggested that, in many cases, cholangitis is responsible for subsequent
immunologic reactions (Popper and Schaffner, 1970).

Developmental Aspects of Hepatic Drug Metabolism
Clinical problems associated with pharmakokinetic differences between the perinatal period and postnatal development through adulthood
have become increasingly apparent in recent years.
are exceptions.

As always, there

Yet, it is common for plasma half lives to be up to a

magnitude greater in the neonate, apparent volumes of distribution to
be substantially increased, and various drug metabolism processes to be
sluggish compared to adulthood (Done et al., 1977).

Unless dosage is

adjusted accordingly, substantial toxicity is likely to occur in children as a result of extraordinarily high plasma drug levels.
Investigation of developmental aspects of pharmacokinetic parameters in animals has largely been supportive of human data.
changes in drug

disposi~ion

Although

and excretion probably contribute (Niems

et al., 1976), pharmakokinetic differences during development are
largely a result of differences in drug metabolism.

Striking variations

10
occur during rat development in both biosynthetic reactions such as
glucuronidation (Dutton, 1978) and oxidative reactions of the cytochrome P450 monooxygenase system (Niems et al., 1976).

This review

will concern itself with the latter.
Although the pattern of variations in monooxygenase activity in
the liver varies with substrate, sex, and species, certain generalizations can be made.

Activity of microsomal enzymes usually begins to

increase at birth, after which it either continues to rise, reaching
a plateau at maturity, or peaks, returning to a plateau with maturation
(Kato and Takanaka, 1968; Niems

~al.,

1976).

Although the metabolism

of a few drug substrates, such as the hydroxylation of aniline in the
rat, peaks as early as two weeks postnatal

(Gram~

al., 1969), others,

such as the N-demethylation of aminopyrine in the rat, peak as late as
nine weeks (Henderson, 1971).

Somewhere during three to eight weeks

postnatal, adult levels of P450 monooxygenase capability is reached for
most substrates (Gilette and Stripp, 1975).
Various mechanisms have been proposed for decreased oxidative
drug metabolism in young animals.

Livers removed from rats injected

with somatotropin demonstrated impaired in vitro microsomal metabolism
of various drug substrates (Wilson, 1969) .

Since levels of growth

hormone decrease postnatally, somatotropin may play a permissive role
in the developmental variations in drug metabolism.

Pelkonen (1973)

suggests that "endogenous ligands" in fetal liver contribute to
decreased drug oxidations following the observation that binding
spectra of aminopyrine in fetal liver are the inverse of the characteristic type I spectra.

11
Biliary Excretion
Biliary excretion has been shown to be a major route for the
elimination of xenobiotics from the body in both animals and humans
(Stowe and Plaa, 1968).

Bile production arises from the active secre-

tion of bile salts by hepatocytes, which is accompanied by the secretion
of water and electrolytes (Levine, 1978).

Three apparently distinct

transport processes have been recognized for the excretion in the bile
of cationic, amnionic, and polar, but uncharged, molecules all with a
minimum molecular weight somewhere between 200-300 (Levine, 1978).
Subsequent to biliary excretion, xenobiotics may be excreted in the
feces or, those with appropriate chemical properties, may be reabsorbed
to enter the enterohepatic circulation.

Compounds which enter this

circulation tend to have prolonged half lives which may contribute to
toxicity.

In addition, this circulation has been shown to be prerequi-

site for the development of certain toxic reactions.

Thompson et al.

(1954) found that chloramphenicol, subsequent to hepatic metabolism
and biliary excretion, is converted to a toxic metabolite in the gut
and reabsorbed as such to produce thyroid hypertrophy and resultant
metabolic disturbances.
Substantial species variation has been observed in the biliary
excretion of some compounds.

Russell and Klaassen (1972) have shown

that the bile/plasma concentration gradient of ouabain following
administration to rats, rabbits, and dogs was four orders of magnitude
greater in the rat than the latter two species.

Observed differences

in the monkey and rabbit in the biliary excretion of disodium chromo-
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glycate, a drug not subject to hepatic metabolism, suggests that species
variation of xenobiotic excretion in the bile in not necessarily due to
interspecies metabolic differences (Ashton et al., 1973).
Hepatic metabolism plays a role in the biliary excretion of many
xenobiotics.

The contribution is most pronounced when compounds are

increased in molecular weight and/or acquire a polar group through
metabolism without which biliary excretion would not occur.

This has

been demonstrated in rats with compounds such as biphenyl (Millburn
et al., 1967) and orphenadrine (Hespe and Kafoe, 1970).

In both cases,

the parent compound is not excreted in the bile unchanged although its
hydroxylated and glucuronidated metabolites are excreted extensively.
Decreased or absent bile flow occurs in cholestasis.

The condition

presents itself morphologically as bile plugs (Popper and Schaffner,
1970) and biochemically as an elevation of serum alkaline phosphatase
due to induction of this enzyme (Kaplan and Righetti, 1970).

Chole-

stasis may be either extra- or intrahepatic, the former being associated
with an obstruction such as a tumor or inflammatory lesion outside the
liver.

In either case, a cormnon disturbance of the secretion of bile

salts and lipid micelles is thought to exist (Popper and Schaffner,
1970).

Organotin Toxicity
Extensive investigation of the toxicity of organotin derivatives
began in the mid 1950s.

The impetus for this was the "Stalinon"

disaster in France in 1954.

The available information regarding the

13
incident is reviewed by Barnes and Stoner (1959).

"Stalinon" was the

propriety name for a drug sold for the treatment of skin infections.
It was said to contain 15 mg/capsule of diethyltin diiodide.

According

to the recommended dosage, patients should have received approximately
90 mg/day of this organotin; in reality, they ingested approximately
80 mg/day of diethyltin and 10 mg/day of the contaminant triethyltin.
Patients exhibited symptoms of both central nervous system and gastrointestinal toxicity, which resulted in approximately 100 deaths.
In the 25 years since "Stalinon", investigations of organotins
have revealed that both diversified and relatively potent toxicity
results from these compounds; reviews are available on the subject
(Barnes and Magos, 1968; McCollister and Schober, 1975; Kimbrough,
1976).
Organotin derivatives have been adopted for a variety of industrial
uses in recent years.

They have been used as stabilizers in the produc-

tion of polyvinyl chloride; catalysts in the making of polyurethane
(Piver, 1973); and as miticides, fungicides, and anthelmintics
(McCollister and Schober, 1975; · Hunter, 1976).

Since many of these

biocides ultimately may contaminate food products, acceptable daily
intakes have been established for organotin pesticides by the FAO/WHO
Joint Expert Committees on Pesticide Residues (McCollister and Schober,
1976).

The values established range from 0.5 to 7.5 µg/kg/day, quite

a constrast to the accepted use of organotin compounds a little more
than two decades ago.
The trialkyltins produce central nervous system toxicity, which
has been attributed to reversible interstitial edema of the white
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matter of the brain

(Magee~

al., 1957).

Inhibition of oxidative phos-

phorylation (Aldridge and Street, 1964) and swelling of liver mitochondria (Wulf and Byington, 1975) have been observed in vitro in rat liver
mitochondria with trialkyltin derivatives.

Inhibition of muscular con-

tractility in vitro, associated with disruption of mitochondria, disorganization of muscle fibers, and depletion of neuromicrotubules, has
also been observed (Tan and Ng, 1977).

Tributyltin undergoes oxidative

metabolism by the rat liver microsomal system (Kimmel et al., 1977) to
form metabolites which retain much of the biologic activity of the
parent compound (Aldridge and Street, 1977) or unstable metabolites
which are rapidly destannylated.
Dialkyltin compounds differ from their trialkyl counterparts in
that the primary lesion of the former is biliary and hepatic injury
(Barnes and Stoner, 1958; Barnes and Magee, 1958; Gaunt et al., 1968).
Dibutyltin is the most active in this respect.

Barnes and Magee (1958)

reported bile duct injury and hepatic inflammation two days after oral
administration of dibutyltin dichloride (50 mg/kg).

After six months,

hepatic fibrosis was evident.
In addition to its effects on the liver, Middleton and Platt
(1977) report an inflammatory reaction in rat skin following the application of dibutyltin.

Contact dermatitis from elastic fabrics with a

vinyl chloride polymer component has been attributed to the presence of
a dibutyltin stabilizer (Fisher, 1973).
Seinen et al (1977a) have reported atrophy of the thymus, spleen,
and popliteal lymph node in weaning rats and toxicity to rat thymocytes
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in vitro from dibutyltin.

Thymocyte-dependent immunity in rats was

found to be impaired by dibutyltin administration (Seinen et al., 1977b).
Allograft rejection was delayed, and the response toward t-depdendent
antigen, but not t-independent antigen, was decreased.

These effects

were greater in rats treated pre- and postnatally.
Dialkytin's toxic effects have been attributed to their ability to
inhibit a-keto acid oxidases in liver mitochondria and brain brei of the
rat (Aldridge and Cremer, 1955); inhibition of oxidative phosphorylation
by binding to the adenosine-triphosphatase complex as seen in ox heart
mitochondria (Cain et al., 1977); and impairment of amino acid transport
by binding to membrane sulfydral groups in rat thymocytes (Miller et
al., 1978).
Kimmel et al. (1977) have shown that dibutyltin derivatives undergo
hepatic microsomal monooxygenase metabolism in rats, at least in part.
Metabolism was investigated by Kimmel et al. in rat liver microsomal
system and in vivo in mice using
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c-dibutyltin diacetate.

Unidentified

dialkyl polar metabolites of dibutyltin were suggested to be butylhydroxylated derivatives.

The lesser amount of monoalkyltin recovered

was thought to result from both nonenzymatic destannylation and decomposition of unstable hydroxylated dibutyltin derivatives.

The majority

of labelled dibutyltin administered to mice was recovered in the feces
between 42-90 hours suggesting biliary excretion.

Other investigators

have reported the concentration of dibutyltin in the bile to be slightly higher than plasma levels 18 hours after oral administration in
rats (Barnes and Magee, 1958).
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Naproxen
Naproxen (6-methoxy-a-methyl-2-napthaleneacetic acid) was synthesized by Harrison et al. (1970) in an attempt to provide an improved
antirheumatic drug, an effort which has proven to be successful
(Muirden, 1978).

Naproxen is reported to be more than ten times as

potent as aspirin in preventing carrageenin-induced rat paw edema, a
commonly used test for antiinflammatory activity (Roszkowski et al.,
1971).

Its usefulness is also a function of its relatively long half

life in animals and humans (Runkel et al., 1972) as compared to other
nonsteroidal antiinflammatory drugs.
Roszkowski et al. (1971) suggest that naproxen acts directly at
the site of inflammation.

Although some nonsteroidal antiinflannnatory

drugs have been reported to produce their pharmacological effects at
least partially by glucocorticoid agonist activity, naproxen does not
appear to possess such properties (Feldman, 1978).

Naproxen's effects

in vivo are more likely to be related to its inhibition of prostoglandin synthesis . (Mcintyre

~

al., 1978).

SKF 525A
SKF 525A

(8-diet~ylaminoethyl-diphenyl-n-propylacetate)

has been

shown to inhibit hepatic microsomal metabolism in vivo (Stitzel et al.,
1966), in vitro (Anders and Mannering, 1966a), and in an extracorporeal
system

(Stitzel~

al., 1968).

Anders and Mannering (1966a) suggest

that SKF 525A produces its effects by competitve inhibition with drug
substrates.

However, other investigators have found both noncompetitive
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and competitive inhibition of the same drug substrate using SKF 525A
before and after recrystallization with benzene (Jenner and Netter,
1972).

No explanation was offered for the effect of recrystallization;

the structure of SKF 525A was unchanged.
SKF 525A is not as meticulous in its inhibition of hepatic microsomal metabolism as originally suspected.
dative

It inhibits primarily oxi-

reaction in liver microsomes, but inhibition of some glucoroni-

dations has been reported (Levine et al., 1970).

Its inhibitory effects

do not extend to the metabolism of all drug substrates (Goldstein et
al., 1974).

In addition, its inhibition of drug metabolism appears to

exhibit temporal dependence (Anders and Mannering, 1966b).

Rats

treated with SKF 525A for five days (50 mg/kg/day, i.p.) showed increased hexobarbital metabolism 24 hours after the last dose of inhibitor, and effect which was attributed to induction of microsomal enzymes.
However, when these rats were given a sixth dose of SKF 525A, they
exhibited significant inhibition of hexobarbital metabolism 135 minutes
later.

Based on these results, these investigators suggest that SKF

525A maintains its inhibitory properties with both control and SKF 525Ainduced microsomal enzymes.
SKF 525A has pharmacological effects in addition to those it exerts
on drug metabolism.

Infusion of this inhibitor into the renal artery of

dogs at concentrations of 4 mg/minute and 8 mg/minute increased urine
volum~

and sodium excretion, respectively (Marshall and Williamson,

1964).

Magus and Fouts (1967) reported that SKF 525A has variable

effects on tryptophan pyrrolase including induction and "deattenuation"
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of hydrocortisone induction of this enzyme in rat liver.

This inhibitor

has also been reported to impair gastrointestinal absorption of drugs in
rats (McLean and Marchand, 1970).
Biliary excretion of stilbestrol, phenolphthalein (Levine et al.,
1970), and 3-methylcholanthrene lLevine, 1972) was decreased in rats as
a result of SKF 525A administration.

This effect was thought to occur

as a result of SKF 525A's effect on metabolism of these drugs since
this inhibitor had no effect on the biliary excretion of administered
phenolphthalein glucuronide (Levine et al., 1970).

Hespe and Kafoe

(1970) investigated the possibility that SKF 525A, or a metabolite,
produced its effects on biliary excretion by competition for elimination in the bile.

Following the finding that SKF 525A enhances biliary

excretion of labelled orphenadrine, they testad the effects of pretreatment with unlabelled orphenadrine and found that excretion of the
labelled compound was unchanged.

This suggests that SKF 525A does not

enhance elimination of compounds in the bile by competition with a
saturable transport process.

EXPERIMENTAL

Materials
Di-n-butylin dichloride was purchased from Aldrich Chemical
Company (Milwaukee, WI).

Naproxen (NAPROSYN) was a product of Syntex

Laboratories (Palo Alto, CA).

SKF 525A was provided by Smith, Kline,

and French Laboratories (Philadelphia, PA).
The following radioactive materials were purchased from New
3
England Nuclear (Boston, MA): 2,3- H-proline (specific activity 20 Ci/
3

mmole), 4- H-proline (specific activity 25-30 Ci/mole) and
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Cr-sodium

chromate (specific activity 200-500 Ci/g).
Reagents purchased from Sigma Chemical Company (St. Louis, MO)
included 2,3-dimercaptopropanol, 2-amino-2-methyl-l-propanol, p-nitrophenol, and p-nitrophenylphosphate.

Dulbeccos Modified Eagles Medium

(DME), RPMI 1640, and phytohemagglutinin were products of Grand Island
Biologicals (Grand Island, NY).
Calbiochem (La Jolla, CA).

Concanavalin A was a product of

FITC-conjugated anti-rat immunoglobulinG

(IgG) was purchased from Miles Yeda, Ltd. (Rehovat, Israel).

Eastman

Kodak (Rochester, NY) was the supplier of 2,4-dinitrophenyl hydrazine.
All reagents used throughout the investigation were analytical grade.

Animals
Male CD-Crl:CD(SD)Br rats were purchased from Charles River
19
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Breeding Laboratories (Wilmington, MA).

The rats were housed in groups

of four to . six in colony cages at an ambient temperature ranging from
24-27°C with alternating 12-hour light/dark cycles.

Rats were fed

Charles River Rat-Mouse-Hamster Formula and water ad libitum.
Rats were 9 weeks of age at the start of treatment in all studies
unless specified otherwise.

Dibutyltin-induced Hepatic Fibrosis
Fibrosis and associated liver injury were produced in rats by the
oral administration of di-n-butyltin dichloride (DBT) in corn oil at a
dose of 20 mg/kg.

Unless otherwise specified, 0 to 4 day DBT adminis-

tration was on a daily basis and 12-day treatment on alternate days.
Between 20-24 hours after the last administration of DBT, rats were
killed by decapitation or, where serum assays were performed, by
ether anesthesia and subsequent exsanguination.

Livers, and sometimes

thymuses and spleens, were removed and quickly chilled.

Sections of

liver tissue, and on occasion feet, were fixed and prepared for light
microscopy with hematoxylin-eosin and trichrome stains.

Liver samples

were also prepared for determination of prolyl hydroxylase activity and
in vitro collagen synthesis.

Blood was added to vials containing 8.2

mg disodium EDTA in 0.1 ml water for leucocyte counts or kept on ice for
approximately 30 minutes and centrifuged at 3000 rpm to obtain serum.

Additional Animal Treatments
Naproxen was administered at a dose of 15 mg/kg every 12 hours by
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oral intubation for 12 days.
in corn oil.

It was prepared as a 7.5 mg/ml suspension

Controls received equivalent amounts of vehicle.

SKF 525A was injected intraperitoneally at a dose of 50 mg/kg in
saline every 12 hours for 4 days.

Controls received equivalent amounts

of saline.
All drugs, regardless of the route of administration, were given
in a volume of less than 1 ml.

Preparation of Substrate for Prolyl Hydroxylase Assay
The tritium labelled substrate was prepared by the method of
Hutton et al. (1966) with some modifications.

Twenty-five to 30 dozen,

7-day old decapitated chick embryos were placed in ice-cold KrebsRinger buffera (Stone and Meister, 1962).

After washing twice with

ice-cold Krebs, embryos were minced in the presence of a small amount
of ice-cold Krebs.

Five to 6 gram portions of minced embryo were

placed in 50 ml beakers and enough Krebs buffer was added to bring the
final volume to 20 ml.

3
Following the addition of 1.0 mCi of 4- H pro-

line and 20 µl of 1.0 M a,a-dipyridyl in ethanol, the mixture was incubated for 2 hours at 37°C under o -co (95/5%) in a metabolic shaker.
2
2
After two hours, the embryo minces were centrifuged at 30,000 rpm for
90 minutes and the supernates discarded.

Newly synthesized collagen

was extracted from the pellet with 0.5 M acetic acid (2 ml/g tissue)
overnight at 4°C.

After centrifugation for 90 minutes at 30,000 rpm,

aNaCl, 1.285 g; KCl, 0.224 g; MgS0 , 0.144 g; CaC1 , 0.1444 g;
2
4
KH Po , 0.544 g; NaHco , 2.10 g; D-glucose, 1.80 g; and distilled water
2 4
3
to 1 liter.
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the supernate containing newly-formed, unhydroxylated collagen was
dialyzed against 10 volumes of 0.01 M Tris HCl buffer (pH 7.4) with at
least four changes.

The substrate was then autoclaved for 15 minutes

and redialyzed against three changes of 10 volumes of Tris HCl buffer
(pH 7.4).

Substrate was then calibrated for specific activity and line-

arity with a standard purified rabbit enzyme (Chichester et al., 1976)
and frozen in 10 ml aliquots.

Prolyl Hydroxylase Activity
Immediately after rats were sacrificed, livers were removed and
40-50 mg aliquots of tissue were homogenized in 600 µl of buff er containing 0.25 M sucrose, 10
and 0.1% Triton.

-5

M disodium EDTA, 10

-5

M dithiothreitol,

Prolyl hyroxylase activity in 50 and 100 µl aliquots

of homogenate was determined by the method of Hutton et al. (1966) with
some modifications.

Aliquots of liver homogenates were incubated at

30°C for 30 minutes in a mixture containing approximately 600,000 cpm
(depending on substrate batch) of tritiated collagen substrate (O.l ml),
1.0 mM ascorbate, 0.1 mM

~-ketoglutarate,

0.1 mM ferrous ammonium sul-

fate, 0.05 M Tris CHl buffer (pH 7.4), 0.2% bovine serum albumin and
0.04% catalase.

The prolyl hydroxylase reaction was stopped after 30

minutes by the addition of 0.1 volume 50% trichloracetic acid.

Tritia-

ted water was then collected by vacuum distillation; a measured fraction of tritiated water was counted for radioactivity in a Packard TriCarb Liquid Scintillation Spectrometer (Model 3310).

This radioactivity

reflects the stoichiometric formation of hydroxyproline and tritiated
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water by prolyl hydroxylase in the presence of cofactors and labelled
substrate as described above (Rhoads and Udenfriend, 1970).

Due to

variability in substrate batches, a conversion factor, derived from substrate calibration with standard enzyme, was employed to permit comparisons of prolyl hydroxylase activity values when different substrate
preparations are used.

Values were then converted to International

Units which are defined as "that quantity of enzyme that will catalyze
the reaction of one µmole of substrate per minute" (Kachmar and Moss,
1976).

In Vitro Collagen Biosynthesis
Collagen and noncollagen protein synthesis by liver tissue in vitro
was determined by the method of Diegelmann et al. (1975) with modifications.

Approximately 20 mg of freshly dissected liver minces were incu-

bated for 24 hours at 37°C under

o2-co2

(95/5%) in 4 ml of Dulbecco's

3
Modified Eagles medium (DME) containing 2,3- H-proline (50 µCi/ml),

0.56 mM ascorbate, and 0.71 mM S-aminopropionitrile.

Experiments have

been conducted confirming that label incorporation into collagen and
noncollagen protein is linear against time between 6 and 24 hours; the
percent label in collagen does not change during this 24 hours (Mann et
al., 1979).

The incubation mixture was frozen, thawed, and homogenized

in a Bellco glass/glass homogenizer.

It was then dialyzed against 100

volumes of 0.5 M acetic acid, containing 10-

5

M disodium EDTA, with two

changes and against 100 volumes of 0.05 M Tris HCl buffer (pH 7.4),
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containing 2.5 mM n-ethylmaleimide, with two changes to remove unincorporated labelled proline.

Tubes of 0.4 ml aliquots of sample were then

incubated for 18 hours at 37°C in a mixture containing 0.05 Tris HCl
buffer (pH 7.4), 2.5 mM n-ethylmaleimide, 0.5 mM calcium chloride, 0.1
mL chloroform and 130 units of bacterial collagenase in a final volume
of 1.0 ml.

Duplicate tubes were incubated without collagenase.

Following incubation, the reaction was stopped and protein was coprecipitated with 0.1 volume bovine serum albumin (1.0%) by the addition of
one volume 10% trichloroacetic acid.

After 30 minutes on ice, samples

were centrifuged at 5,000 rpm for 30 minutes.
in 2 ml Digestol
Hydromix

R

R

The pellet was digested

(Yorktown, Hackensack, NJ) and counted in 10 ml

scintillation cocktail (Yorktown, Hackensack, NJ),

The 5%

trichloroacetic acid supernate was again coprecipitatea using bovine
serum albumin (1.0%) and counted in 10 ml HydromixR.
was determined on liver homogenates.

Protein content

Collagen and noncollagen protein

synthesis per unit protein were calculated from collagenase-digested
protein in the supernate and collagenase-resistent protein in the
pellet, respectively.

Relative collagen synthesis was calculated using

a formula which accounted for the relative enrichment of collagen proline/hydroxyproline content (5.4 times) compared to noncollagen protein
as follows (Diegelmann et al., 1975):

% collagen =
cpm in supernate
x
100
(cpm in pellet x 5.4) + (cpm in supernate)
synthesis

25
Protein Determination
Protein content was determined by the method of Lowry et al.,
(1951) using bovine serum albumin as the protein standard.
sity of the characteristic blue color was read at 750

m~

The inten-

on a Gilford

250 Sprectrophotometer.

Serum Alanine Transaminase
Serum alanine transaminase was determined by the method of
Reitman and Frankel (1957).

Serum (0.2 ml) was incubated at 37°C for

30 minutes with 1.0 ml substrate containing 2.0 µmoles/ml a-ketoglutarate and 200 µmoles/ml alanine.

One ml of 2,4-dinitrophenylhydrazine

(1.0 µmole/ml) was added to each tube and samples were left at room
temperature for 20 minutes after which 10 ml of 0.4 M NaOH was added.
Following 30 minutes for color development, absorbance at 520 mµ was
determined.

Both reagent and serum blanks were prepared and all samples

compared to a standard curve ranging from 0-1.0 µmoles of pyruvate.
Values were then converted to International Units.

Serum Alkaline Phosphatase
Alkaline phosphatase in serum was determined by the two-point
modification (Kachamar and Moss, 1976) of McComb and Bowers' (1972)
continuous monitoring procedure with some additional modifications.
Serum (20 µl) was incubated for 30 minutes at 37°C with 0.5 ml of
buffered substrate containing 14.0 mM p-nitrophenylphosphate and 0.5
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mM MgC1

in 0.625 M 2-amino-2-methyl-l-propanol {pH 10.25). After 30
2
minutes, five ml of 0.05 M NaOH were added to each tube. Duplicate
tubes {blanks) were prepared with the addition of serum as the final
step.

Absorption for test and blank tubes was determined at 405 mµ

for calculation of tJ.A (A

A.
)
test - -olank •

The absorption differences were

compared to a standard curve determined using p-nitrophenol; values
ranged from 0.45 to 3.15 µmoles p-nitrophenol.

Values were then con-

verted to International Units.

Leucocyte Determination
The number of leucocytes in whole blood was determined by dilution
of 0.1 ml of whole blood in 1.1 ml of 0.5% acetic acid containing gentian violet and quantitation in a hemocytometer chamber.

Lectin-dependent Lymphocyte-mediated Cytolysis
Lectin-dependent lymphocyte-mediated cytolysis was determined by
the method of Davignon and Laux (1978).

Effector cells were prepared

from spleens removed from control and DBT-treated rats.

These were

kept at 4°C in RPMI 1640 complete for no longer than 2 hours prior to
assay.

A crude preparation of lymphocytes was expressed from spleens

with a rubber policeman.

Cells were washed and then resuspended in

medium containing 0.83% ammonium chloride in 0.01 Tris base to lyse red
blood cells.

The remaining cells were washed three times and resuspen-

ded in medium at a concentration of 5

x

10

6

cells/ml.
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Cr-target cells were prepared from an intraperitoneal inoculum
b

of EL4 leukemic cells in syngeneic mice (C56BL/6[H-2 ]).
(5-10

x

These cells

6
10 ) were incubated for 60 minutes at 37°C with 100 µCi of

sodium chromate.
Samples were prepared and incubated for 4 hours in a reaction mixture containing 5 x 10

5

effector cells, 2 x 10

4

target cells, and 1.0 µg

of phytohemagglutinin (PHA) or concanavalin A (Con A) in a final volume
of 0.3 ml.

Spontaneous lysis and 100% lysis were determined by replac-

ing effector cells with medium and distilled water, respectively.

After

incubation, each mixture was diluted to 2.0 ml with RPMI 1640 and 1.0 ml
was counted in a Beckman Gamma 300 Counter.

Percent lysis was calcula-

ted with the following formula:
Percent
=
Ly sis

Sample
Ly sis
100%
Lysis

Spontaneous
Lysis
Spontaneous
Lysis

Delayed Hypersensitivity
Rats were tested for delayed-type hypersensitivity to DBT by footpad injection (Turk, 1980).
DBT was prepared for foot-pad injection by dissolving in ethanol
(100 mg DBT/ml) and adding to 0.25 M sucrose with 0.05 M Tris HCl
(pH 7.5) for final concentrations of 5 mg DBT/ml and 5% ethanol.

Liver

was prepared for injection by homogenizing 1.0 g tissue in 5.0 ml 0.25
M sucrose/0.05 M Tris HCl (pH 7.5), adding ethanol, and diluting to a
final concentration of 20 mg liver/ml and 5% ethanol.

Liver conjugated
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with DBT was prepared by incubating a mixture of DBT (5 mg/ml) and liver
(2a mg/ml) in a.25 M sucrose/a.a5 M Tris HCl (pH 7.5) for 1 hour at 4°C.
Binding of DBT to liver was established by dialyzing preparations
of liver, DBT, and DBT/liver, similar to those described above, against
a.as M Tris HCl (pH 7.5) with two changes and quantitating retained DBT
by atomic absorption spectrophotometry (Perkin Elmer Model 46a Atomic
Absorption Spectrophotometer).

DBT/liver samples were also dialyzed in

the presence of dimercaprol (12 mg/ml) to assure that the DBT was permeable to the dialysis tubing in spite of its relative insolubility.
Samples were prepared for spectrophotometric analysis according to the
method of Murthy et al. (1973) by digestion in concentrated nitric acid
until clarity, evaporation to near dryness, and dilution in 5% nitric
acid.

Tin metal dissolved in la% HCl was used as a standard.
Delayed-type hypersensitivity was determined by challenging control

and DBT-treated rats with a.1 ml vehicle, liver, DBT, or DBT/liver in
the right foot-pad 13 days after the start of DBT treatment.

Foot-pad

swelling was assessed by volume displacement, using a solution of
Wright's stain for visibility, and right/left foot volume ratios were
calculated.

Immunofluorescence
Direct inununofluorescence (Kawamura, 1977) against rat IgG was
performed on control and DBT-treated rat livers using Raine's variation
of this standard method (personal communication).
prepared from fresh liver and cut at 4 µ.

Frozen sections were

Tissue was placed in acetone
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for 10 minutes, 95% ethanol for 20 minutes, and rinsed twice in phosphate buffered saline.

Duplicate slides were incubated with control

rat serum for 30 minutes at room temperature after which all slides
were incubated for 30 minutes at room temperature with fluorescented
rabbit anti-rat IgG (F/P = 4.1).

After rinsing twice with phosphate

buffered saline, slides were coverslipped with Aqua MountR (Lerner Labs,
Stamford, CT), nonfluorescing medium.

Statistical Methods
Statistical analyses performed included Students' t-test, linear
regression, analyses of variance (one-way and multifactorial classifications), and Newman Keuls pairwise comparisons.

Acceptable level for

a test of significance in these studies was at P<0.05.
cable to these analyses follow:
a)

Mean = x = Ex/n

b)

Variation= E(x-X)

c)

Variance = E(x-x)

d)

Standard Deviation = s =

e)

Standard Error of x = sx =

f)

Regression Equation = yx = a + bx

g)

Correlation Coefficient

2

2

= Sum of Squares = SS
= Mean of Squares = MS

~

v~

=r

s/A[D.

= SEM

=J7 :j-1 -

_r.

2
_CY_-_Yx_)_

E (y-Y)2

Formulae appli-
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h)

Students' t statistic = t =

J
i)

xl - X2

ss 1 + ss 2

-1 + 1
2
nl + n2 n2
nl

Studentized Range Statistic = q = T
large

T

small

1} MSerror/n
j)

One-way Analysis of Variance * (ANOVA)
SS

df

MS

Between

2
2
L:T. /n-G /kn

k-1

SS/k-1

Within

2
2
Hx. -L:T. /n

k(n-1)

SS/k(n-i)

Total

2 2
Hx. -G /kn

kn-1

SS/kn-1

J

J

J

J

F
MSbe/MSWI

F [k-1,k(n-l)]
i)

2

x

2 Analysis of Variance * (ANOVA)
SS
2

2

df

MS

A

L:A /nq-G /npq

p-1

SS/p-1

B

2
2
L:B /np-G /npq

q-1

SS/q-1

AB

2
2
2
2
L:(AB) /n-L:A /nq-L:B /np+G /npq

(p-1) (q-1)

SS/(p-l)(q-1)

Error

2
2
HL:x -L: (AB) /n

pq(n-1)

SS/pq(n-1)

Total

2 2
HL:x -G /npq

pqn-1

SS/pqn-1

FA= MSA/MSE

F[p-l,pq(n-1)]

FB = MSB/MSE

F[q-1,pq(n-l)]

FAB = MSAB/MSE

F[(p-l)(q-1),pq(n-l)]

*The necessary corrections for unequal n were made by Statistical
Analysis Systems (SAS), University of Rhode Island.

RESULTS

0 to 4 Day Studies
Since prolyl residues have been shown to be hydroxylated subsequent
to incorporation into procollagen (Prockop and Juva, 1965) and such
hydroxylation does not occur to a significant extent in noncollagen protein, prolyl hyroxylase activity (PHA) can be used as a measure of collagen synthesis in rat liver.

The effect of DBT administration from 0

to 4 days on PHA in rat liver homogenates is shown in Figure 1.

There

was a gradual increase in activity reaching greater than 220% of control
by day 4.
Although PHA has been shown to be a sensitive indicator of collagen
synthesis in the liver (Mann et al., 1979), a more direct indication of
absolute and relative collagen synthesis is obtained by measurement of
in vitro incorporation of 3H-proline into collagenase-degradable and
collagenase-resistant protein (Diegelmann et al., 1975).

A gradual

3
increase in collagen synthesis, reflected by 2,3- H-proline released
from liver protein by collagenase, was observed from 0 to 4 days of DBT
administration reaching approximately 500% of control by day 4 (Figure
2).

This was not accompanied by an increase in noncollagen synthesis,

3
as measured by incorporation of 2,3- H-proline into collagen-resistant
protein.

There was a significant correlation (r=0.94) between the acti-

vity of prolyl hydroxylase and in vitro collagen synthesis (Figure 3).
Since elevated serum alanine transaminase is commonly associated
with hepatic inflammation (DeRitis et al., 1965), the activity of this
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Figure 1.

EFFECT OF DIBUTYLTIN'1 (DBT) ON HEPATIC PROLYL HYDROXYLASE ACTIVITYb IN
RATS AFTER 0 TO 4 DAYS OF TREATMENT.
a) DBT in corn oil was administered at a dose of 20 mg/kg/day, p.o.;
controls received equivalen amounts of corn oil.
b) Enzyme activity in liver homogenates was quantitated by tritium
release assay from labelled collagen substrate as described in the
methods.

Seven experimental animals were used per day.

Values are mean

+ S.E.M.

Analysis of variance, one-way classification for the treatment

variable day, significant at P<0.05.
c) Significant at P<0.05 vs. control (Newman Keuls pairwise comparisons).
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Figure 2.

EFFECT OF DIBUTYLTINa (DBT) ON IN VITRO COLLAGEN AND NONCOLLAGEN PROTEIN
SYNTHESISb IN RAT LIVER AFTER 0 TO 4 DAYS OF TREATMENT.
a) DBT in corn oil was administered at a dose of 20 mg/kg/day, p.a.;
controls received equivalent amounts of corn oil.
b) Collagenase digestion was performed on homogenates of liver minces
3
following 24 hour incubation with 2,3- H-proline as described in the
methods.

Collagen is represented by label in supernate as a result of

collagenase digestion.

Noncollagen protein is represented by labelled

collagenase-resistant protein in the pellet.

Three experimental animals

were used per day except for control where two were used.
mean + S.E.M.

Values are

Analysis of variance, one-way classification for the

treatment variable day, significant at P<0.05 for the response variable
collagen.
c) Significant at P<0,05 vs. control and day 1 (Newman Keuls pairwise
comparisons).

1'! 2,3 [3t-f J PROUNE RELEASED FROM
LJ LIVER PROTEIN BY COLLAGENASE

D

2,3 [~] PROUNE INCORPORATED INTO
COLLAGENASE- RESISTANT PROTEIN
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Figure 3.

CORRELATION BETWEEN HEPATIC PROLYL HYDROXYLASE ACTIVITY AND IN VITRO
COLLAGEN SYNTHESISa.
a) Each point represents mean+ S.E.M. of prolyl hydroxylase activity
and in vitro collagen synthesis on the specified day of treatment.
Experimental details are described in Figures 1. and 2. and the methods.
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enzyme was determined in serum from rats after 4 days of DBT administration.

An increase in serum alanine transaminase of approximately 400%

of control was observed at this time (Table 1).
Histological observations of livers from rats treated with DBT for
0 to 4 days revealed increasing frequency of the appearance of periportal inflammation and bile duct proliferation during this period (Figures
5 and 6) as compared to control (Figure 4).

The infiltration of pre-

dominantly polymorphonuclear cells was extensive in the proximity of
ductular cells.

12-Day Studies
The effect of DBT on parameters of hepatic collagen metabolism
after 12 days of treatment is shown in Table 2.
been described previously (Yermakoff, 1978).

These results have

The activity of prolyl

hydroxylase was increased to nearly 150% of control in DBT-treated rats.
There was no significant change in either the amount of label released
from liver protein by collagenase or the amount incorporated into collagenase-resistant protein.

However, the percent of total labelled pro-

tein digested by collagenase was increased approximately two-fold in
animals treated with DBT, reflecting a change in these two parameters
relative to each other.

Finally, DBT produced a greater than

two~fold 

increase in hepatic hydroxyproline content, representing an increase in
collagen accumulation.
Since certain serum enzymes have been shown to be useful indicators
of both the degree and type of liver injury (DeRitis et al., 1965),

Table 1.

Effect of dibutyltin dichloridea (DBT) on serum alanine
transaminaseb (ALTA) after 4 days of treatment.
ALTA

No. of
Rats

(mIU /0. 2ml)

Control

6

6.18 + 0.32

DBT

5

23.00 + 3.44c

Group

aoBT was administered at a dose of 20 mg/kg/day, p.o.; controls
received equivalent amounts of corn oil.
bserum ALTA was determined colorimetrically as described in the
methods. Values are mean + S.E.M.
csignificant at P < 0.05 vs. control (two-tailed Student's t-test).
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Figure 4.

PHOTOMICROGRAPH OF LIVER FROM A CONTROL RAT SHOWING A CENTRAL VEIN AND
PORTAL TRIAD.

TRICHROME STAIN x 100.
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Figure 5.

RAT LIVERS AFTER 1 DAY (A) AND 2 DAYS (B) OF DBT ADMINISTRATION
(20 mg/kg/day, p.o.).

PERIPORTAL INFLAMMATION AND DISORGANIZATION OF

DUCTULAR CELLS ARE APPARENT IN (B),

TRICHROME STAIN x 100,
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Figure 6.

PHOTOMICROGRAPH OF RAT LIVERS AFTER 3 DAYS (A) AND 4 DAYS (B) OF DBT
ADMINISTRATION (20 mg/kg/day, p.a.).

DISORGANIZED DUCTULAR CELL PRO-

LIFERATION AND PERIPORTAL INFLAMMATION ARE SEEN IN (A) AND, MORE PERVASIVELY, IN (B).

TRICHROME STAIN x 100.

Table 2.

Effect of dibutyltin dichloridea (DBT) on parametersb of
hepatic collagen metabolism after 12 days of treatment.
Control

Prolyl Hydroxylase Activity
(mU/mg protein)

0.282 + 0.010
(10)

DBT

0.412 + o.029c
(12)

In Vitro Collagen Synthesis
4-3H-proline released from liver
protein by collagenase
(cpm/mg protein)

(6)

440 + 75
(5)

4-3H-proline incorporated into
collagenase resistant protein
(cpm x 10-3/mg protein)

19.2 + 3.0
(6)_

13.4 + 0.9
(5)

% total labelled protein digested
by collagenase

0.30 + .0.08

0.59 + 0.08C
(5)

Hydroxyproline Content
(ug/g liver wet weight)

307 + 81

(6)

125 + 4
(6)

266 + 4c
(6)

aDBT was administered in corn oil 20 mg/kg, q.o.d., p.o.; controls
received equivalent amounts of corn oil.
bnata and methods have been described previously (Yermakoff, 1978).
Values are mean+ S.E.M.
csignificant vs. control at P < 0.05 (two-tailed Student's t-test).
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alanine transaminase and alkaline phosphatase activities were determined
in serum from DBT-treated rats after 12 days of administration.

There

was no significant elevation in the activity of either of these two
enzymes in treated animals (Table 3).
Histological changes in these rats included extensive infiltration
of both polymorphonuclear and mononuclear cells, proliferation and injury to ductular cells, and fibrosis within the portal tracts (Figures
7 and 8).
The effect of the nonsteroidal antiinflammatory drug, naproxen, on
the activities of prolyl hydroxylase and alanine transaminase when administered alone and in combination with DBT for 12 days is shown in
Figure 9.

DBT produced an increase in PHA which was 146% of control,

while naproxen had no significant effect on the activity .of this enzyme.
Naproxen and DBT administered together produced an increase in PHA that
was 127% of control.

The interaction between these two compounds was

not significant as measured by multifactorial analysis of variance with
the treatment variables DBT and naproxen.

However, there was no signi-

ficant difference between PHA in the naproxen and DBT/naproxen groups.
The activity of serum alanine transaminase was not elevated in any
group.

Age-related Studies
Since DBT has been shown to produce thymotoxicity and impaired
cell-mediated immunity in rats treated with DBT pre- and postnatally
(Seinen et al., 1977b) and immunologic processes were suspected in

Table 3.

Group

Serum enzymes after 12 days of dibutyltin dichloridea (DBT)
administration.
Alanine Transaminaseb
Activity (mIU/0.2ml)

o. 25

Control

4. 98 +

DBT

6.26 + 1.05 (9)

Alkaline Phosphataseb
Activity (mIU/ml)
266 + 19 (8)

(7)

268 + 27 (10)

aDBT was administered at a dose of 20 mg/kg, q.o.d., p.o.; controls
received equivalent amounts of corn oil.
bEnzyme activity was determined colorimetrically as described in the
methods. Values are mean+ S.E.M.
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Figure 7.

A PORTAL TRACT AFTER 12 DAYS OF DBT ADMINISTRATION (20 mg/kg/day,

p.a.).

FIBROUS TISSUE SURROUNDS THE PORTAL VEIN.

PERIPORTAL INFLAMMA-

TION IS EXTENSIVE AND DISORGANIZED DUCTULAR CELL PROLIFERATION IS APPARENT.

TRICHROME STAIN

x

100.
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Figure 8.

PORTION OF A PORTAL TRACT AFTER 12 DAYS OF DBT ADMINISTRATION (20 mg/kg,
q.o.d., p.o.).
DUCTULAR CELLS.

INFLAMMATORY CELLS SURROUND INJURED AND PROLIFERATING
TRICHROME STAIN x 100.
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Figure 9.

EFFECTS OF DIBUTYLTINa (DBT) AND NAPROXENa (NAP) SEPARATE AND COMBINED
ON HEPATIC PROLYL HYDROXYLASE ACTIVITYb AND SERUM ALANINE TRANSAMINASE
ACTIVITYc IN RATS AFTER 12 DAYS OF TREATMENT.
a) DBT and NAP were administered in corn oil at doses of 20 mg/kg,
q.o.d., p.a., and 15 mg/kg, b.i.d., p.a., respectively; controls
received equivalent amounts of corn oil.
b) Prolyl hyroxylase activity (FHA) was determined in liver homogenates by

3
H-release assay from labelled collagen substrate as described

in the methods.
c) Serum alanine transaminase activity (ALTA) was determined colorimetrically as described in the methods.

All values are mean+ S.E.M.

d) Analysis of variance, multifactorial classification for the treatment variables DBT and NAP and the response variable PHA or ALTA,
significant effect at P<0.05.
e) Analysis of variance, one-way classification for the treatment variable DBT and the response variable PHA or ALTA, significant at P<0.05.
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DBT-induced cholangitis, a possible inverse relationship between these
two phenomena was investigated in age-related studies.

The effect of

DBT on hepatic PHA after 12 days of treatment invarious age groups is
shown in Table 4.

Enzyme activity was 125%, 146%, and 215% of control

in rats 4, 9, and 14 weeks of age at the start of treatment.

Quantita-

tion of peripheral blood leucocytes, presented in Table 5, shows a DBTinduced elevation in these cells only in the rats 9 and 14 weeks of age
at the start of treatment.

The effects of DBT on rat body weight in

these three age groups is compared in Figure 10; there was a significant
difference between control and DBT-treated animals in the 9 and 14 week
groups only.
Hepatic histopathology in rats 14 weeks of age at the start of treatment was similar to that observed in the 9-week old group, which was
described above.

However, the 4-week old group showed little evidence

of the usual histopathalogic lesions induced by DBT.

Periportal inflam-

mation and bile duct proliferation were moderate or absent in these
livers (Figure 11).

Immunolosi
Since DBT has been shown to produce thymotoxicity in weanling rats
following both intravenous administration or incorporation of DBT in
the diet (Seinen et al., 1977b), the effect of DBT on thymus weight in
4-week old rats in the dosage regimen described herein was investigated.
Table 6 shows a striking decrease in thymus weight to less than one

Table 4.

Group

Effect of dibutyltin dichloridea(DBT) on prolyl hydroxylase
activityb(PHA) after 12 days of treatment in rats 4,9, and
14 weeks of age at the start of treatment.
No. of
Rats

PUA
(mU/mg protein)
4

Control
DBT

6
10
9

%

Control

WEEKS
0.307 + 0.018

100 + 6

0.386 + o.014c

125 + 5c

WEEKS

Control

10

0.282 + 0.010

100 + 4

DBT

12

0.412 + o.029c

146 + 10c

14

WEEKS

Control

4

0.136 + 0.016

100 + 12

DBT

8

0.292 + o.044c

215 + 32c

aDBT was administered at a dose of 20 mg/kg, q.o.d., p.o.; controls
received equivalent amounts of corn oil.
bpHA was determined in liver homogenates by the 3H-release assay from
labelled collagen substrate as described in the methods. Values are
mean+ S.E.M.
csignificant at P < 0.05 vs. control (one-tailed Student's t-test).
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Table 5.

Group

Effect of dibutyltin dichloridea(DBT) on leucocyte countb
after 12 days of treatment in rats 4, 9, and 14 weeks of
age at the start of treatment.
No. of
Rats

Leucocytes/cu min
4

%
Control

WE E K S

Control

5

6,450 +

507

100 + 8

DBT

9

5,183 +

793

80 + 12

9

WE E K S

Control

5

12,130 + 1,142

100 +

DBT

5

18,940 + 2,379

156 + 19

1 4
Control

4

DBT

7

9

WE E K S
9,700 + 1,236
12 ,114 +

709

100 + 13
125 +

aDBT was administered at a dose of 20 mg/kg, q.o.d., p.o.; controls
received equivalent amounts of corn oil.
bLeucocytes were quantitated as described in the methods.
are mean + S.E.M.

Values

cSignificant at P<0.05 vs. control (one-tailed Student's t-test).
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Figure 10.

EFFECTS OF DIBUTYLTI~ (DBT) ON RAT BODY WEIGHTb AFTER 12 DAYS OF

TREATMENT.
a) DBT in corn oil was administered at a dose of 20 mg/kg, q.o.d., p.o.;
controls received equivalent amounts of corn oil.
b) The number of experimental animals in each group are shown in parentheses.

Values are mean+ S.E.M. of weight change during DBT treatment.

c) Significant at P<0.05 vs. control (one-tailed Students' t-test).
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Figure 11.

LIVER FROM 4-WEEK OLD RAT AFTER 12 DAYS OF DBT ADMINISTRATION
(20 mg/kg, q.o.d., p.o).

TRICHROME STAIN x 100.
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Table 6,

Control
DBT

a
Effect of DBT on thymus weight in rats 4 weeks of age,
No. of
Rats

Thymus
(g dry weight)

Thymus
(g wet weight)

Body Weight
(g)

· Thymus
(mg/g body weight)

6

0.15 + 0.02

0.82 + 0.11

182 + 14

4.4 + 0.4

10

0,04 + 0.01

191 +

1.3 + 0.2

b

0.25 + 0.04

b

6

b

~BT in corn oil was administered 20 mg/kg, q.o.d., p.o. for 12 days; controls received
equivalent amounts of corn oil. Values are mean + S.E.M.
b

P<0,05 vs. control (two-tailed Student's t-test).

Vl

......
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third of control when measured by wet or dry organ weight.

When normal-

ized for body weight, the decrease in thymus weight is as great.
Immunologic studies of 9-week old rats included determination of
lectin-dependent lymphocyte-mediated cytolysis (Davignon and Laux, 1978).
The assay is a measure of cytotoxic t-cell activity, in which the presence of lectin precludes the requirement for specific target cells.
Lysis of

51

Cr-labelled target cells by cytotoxic t-cells was not appar-

ent in either control or DBT treated rats after 12 days of treatment.
Percent lysis was approximately 0-2% in both groups.
A second parameter of cell-mediated immunity, delayed-type hypersensitivity, was investigated in rats after 12 days of DBT administration.

Challenge doses of DBT were given with this organotin alone or

conjugated to a liver macromolecule.

Equilibrium analysis studies con-

firmed that most of the DBT (94%) in this DBT/liver conjugate is nondialyzable after incubation with liver homogenate as compared to 48%
and 42% without liver and in the presence of dimercaprol, respectively.
After a challenge dose of DBT or DBT/liver conjugate, both controls and
DBT-treated rats showed foot-swelling characteristic of a delayed-type
hypersensitivity response (Table 7).

However, the equivalent responses

in control and treated animals suggested that these results were not due
to an innnunologic response.

Histopathologic observation revealed pre-

dominately polymorphonuclear infiltration and extensive tissue injury
suggesting acute inflammation (Figure 12).
Investigation of antibodies directed against hepatic antigens and/or
DBT in liver from DBT-treated rats was performed by direct immunofluorescence using rabbit anti-rat IgG.

Immunofluorescence was localized to,

Table 7.

Effect of a challenge dosea of dibutyltin (DBT) on rats
after 12 days of DBT administrationb.

Challenge

Ratio Right/Left Foot Volume
CONTROL
DBT

Vehicle

1.0
1.0
1.0

1.0
1.0
1.0

Liver
(2 mg)

1.0
1.0
1.0

1.0
1.0
1.0

DBT
(0.5 mg)

1.3
1. 3
1.3

1.3
1.5
2.3

DBT/Liver
(0.5 mg/2 mg)

1.8
1.8
1.8

1.8
1. 7
1.3

aChallenge dose contained the concentrations of DBT and liver
indicated above in a volume of 0.1 ml; it was injected in the
right foot pad using a 1/4 cc glass syringe and 25 gauge needle.
bDBT was administered at a dose of 20 mg/kg, q.o.d., p. 0.;
controls received equivalent amounts of corn oil.
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Figure 12.

MUSCLE FIBERS IN A NORMAL RAT FOOT (A) AND IN A FOOT 24 HOURS AFTER
INJECTION OF 0.5 mg DBT INTO THE FOOT PAD (B).

ACUTE INFLAMMATION AND

DISORGANIZATION OF MUSCLE FIBERS ARE APPARENT IN (B).
EOSIN STAIN

x

400.

HEMATOXYLIN-
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but equally intense throughout, the portal tracts.

It was suggestive

of a reaction against serum IgG rather than antibodies directed
against a particular hepatic cell type.

Studies with SKF 525A

The possible relationship between differences in hepatic microsomal metabolism and age-related effects of DBT was investigated using
an inhibitor of microsomal enzymes, SKF 525A.

SKF 525A and DBT were

administered alone and concomitantly to rats for 4 days.

The effects

of these treatments on PHA and serum alanine transaminase activity are
shown in Figure 13.

PHA was increased in the DBT group and SKF group

to approximately 220% and 250% of control, respectively.

The activity

of prolyl hydroxylase in the DBT/SKF 525A group was nearly 270% of
control and substantially less than what would be anticipated if their
effects were additive; as determined by a multifactorial analysis of
variance with the treatment variables DBT and SKF 525A, this represented
a significant interactive effect between these two compounds.

There was

no difference in the protein content of liver tissue in all four groups
when measured as mg protein/mg liver wet weight.

Therefore, prolyl

hydroxylase values in the livers of these rats were not a function of
altered protein content.

The increase in alanine transaminase activity

measured in the serum from DBT-treated rats at 4 days time was completely inhibited by SKF 525A.
Observation of livers from SKF 525A-treated rats revealed relatively normal histology (Figure 14).

The only obvious pathology was the

Figure 13.

EFFECTS OF DIBUTYLTINa (DBT) AND SKF 525Aa (SKF) SEPARATE AND COMBINED
ON HEPATIC PROLYL HYDROXYLASE ACTIVITYb AND SERUM ALANINE TRANSAMINASE
ACTIVITYc IN RATS AFTER 4 DAYS OF TREATMENT.
a) DBT in corn oil was administered at a dose of 20 mg/kg/day, p.o.
and SKF in saline at a dose of 50 mg/kg, b.i.d., i.p.; controls received
equivalent amounts of vehicles.
b) Prolyl hydroxylase activity (PHA) was determined in liver homogenates by

3

H-release assay from labelled collagen substrate as described

in the methods.
c) Serum alanine transaminase activity (ALTA) was determined colorimetrically as described in the methods.

Values are mean + S.E.M.

d) Analysis of variance, multifactorial classification for the treatment variables DBT and SKF and the response variable PHA and ALTA,
significant effect at P<0.05 or
e) significant interaction at P<0.05.
f) Analysis of variance, one-way classification for the treatment variable DBT and the response variable PHA or ALTA, significant at P<0.05.
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0

Figure 14.

LIVER FROM A RAT TREATED WITH SKF 525A (50 mg/kg, b.i.d., i.p.) FOR 4
DAYS SHOWING FATTY INFILTRATION.

TRICHROME STAIN x 100.
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presence of fatty infiltration (Figure 15).

Livers from rats treated

with SKF 525A and DBT (Figure 16) were very similar to those in the SKF
525A group.

Fatty infiltration was evident, but periportal inflammation

and biliary injury seen with DBT treatment alone for 4 days (Figure 6b)
were absent.

Figure 15.

FATTY INFILTRATION IN LIVER PARENCHYMAL CELLS AFTER 4 DAYS OF SKF
ADMINISTRATION (50 mg/kg, b.i.d., i.p . ) .

TRICHROME STAIN x 400.
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Figure 16.

PORTION OF A PORTAL TRACT IN RAT LIVER AFTER 12 DAYS OF DBT (20 mg/kg,
q.o.d., i.p.) AND SKF 525A (50 mg/kg, b.i.d., i.p.) ADMINISTRATION.
FATTY INFILTRATION CAN BE SEEN IN HEPATOCYTES.

TRICHROME STAIN x 100.

'

'
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DISCUSSION

Administration of DBT from 0 to 4 days produces a progressive
increase in the two parameters of hepatic collagen synthesis examined,
prolyl· hydroxylase activity (PHA) (Figure 1) and in vitro collagen
synthesis (Figure 2).

The correlation (r=0.94) between these two

parameters (Figure 3) substantiates the predictive value of PHA
as an estimate of hepatic collagen synthesis.

A similar correlation

has been observed in human liver biopsies taken from patients exhibiting both normal and pathological histology (Mann et al., 1979).
The increase in PHA and in vitro collagen biosynthesis from
0 to 4 days are associated with increasing frequency and severity
of histopathologic changes during this period (Figures 4-6).

The

periportal inflammation, present throughout most specimens by day 4,
contains predominantly polymorphonuclear cells and is, therefore,
suggestive of acute inflammation.
seen in the inflammatory area.

Proliferated bile ducts are often

Such proliferation is associated with

many types of liver injury and is considered a characteristic feature
of the fibrotic/cirrhotic process (Masuko et al., 1964).

Although

histologic evidence of fibrosis in these livers is moderate at best,
biochemical data indicate that fibrogenic processes are active after
4 days of DBT treatment.
Serum alanine transaminase is elevated approximately four-fold
in rats treated with DBT for 4 days.

Since increased serum a.lanine

transaminase reflects parenchymal liver injury (Kachmar and Moss, 1976)
61
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and such injury is very rarely observed in livers from DBT-treated
rats unless it is proximal to inflannnatory areas, this increase in
serum enzyme activity is probably a function of the inflammatory
process in the liver.
After 12 days of DBT administration, increases in hepatic PHA,
in the percent of in vitro protein synthesis directed toward collagen,
and in liver hydroxyproline content are observed (Table 2).

The

increase in the activity of prolyl hydroxylase is less than that
observed after 4 days of DBT treatment (146% vs. 221%).
indicative of reversal of liver injury.
to be an early indicator of

This is not

Rather, PHA has been shown

increased hepatic collagen synthesis

both in human liver disease (Mann et al., 1979) and in carbon tetrachloride-induced experimental liver injury (Lindblad and Fuller, 1980).
The approximately two-fold increase in the percent of labelled
protein digested by collagenase appears to be the result of a small
increase in the amount of label released from liver protein by collagenase relative to decreased incorporation into collagenase-resistant
protein; the changes in these latter two parameters, when considered
alone, are not statistically significant.

The increase in histologi-

cally demonstrable fibrosis after 12 days of DBT administration
suggests that the increase in the percent in vitro collagen synthesis
is due to replacement of viable parenchyma with areas of connective
tissue and collagen-producing cells.

Such connective tissue accumula-

tion is also apparent from the increased hydroxyproline content in
these livers.
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Neither of the serum enzyme activities measured in rats after 12
days of DBT administration are significantly elevated above control
values (Table 3).

Since serum alanine transaminase activity usually

reaches peak levels early in liver injury (Kachmar and Moss, 1976),
the low levels of this enzyme at this time are not surprising.
Large increases in serum alkaline phosphatase are observed in
both humans (DeRitis et al., 1965) and rats (Kaplan and Righetti, 1970)
as a result of cholestasis.

This increase in serum alkaline phospha-

tase is thought to be a result of de novo synthesis by the liver of
an isoenzyme of hepatic alkaline phosphatase (Kaplan and Righetti,
1970).

Since alkaline phosphatase is not elevated in serum from rats

administered DBT for 12 days (Table 3), cholestasis does not appear
to be a factor in the cause and/or perpetuation of DBT-induced liver
injury at this time.

Since this enzyme is inhibited by certain heavy

metals (Kachmar and Moss, 1976), in vitro inhibition of alkaline phosphatase activity in control serum by DBT was investigated to ascertain
whether such an effect could be responsible for erroneously low enzyme
activity in DBT-treated rats; no such inhibition could be demonstrated.
Liver histopathology after 12 days of DBT administration (Figures 7 and 8) reveals extensive periportal inflammation; both mononuclear and polymorphonuclear cells are present.

Ductular cell in-

jury and proliferation and fibrosis within the portal tracts are
extensive.

The central veins and parenchyma proximal to them remain

well preserved.

Although the majority of DBT-treated rats exhibit

such a periportal lesion, a small number of animals invariably fail
to do so.

On occasion, granulomatous lesions are observed in livers
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after 12 days of DBT treatment.
The role of inflammation in DBI-induced fibrogenesis was investigated with naproxen, a compound which has been shown to exhibit potent
antiinflammatory and antigranuloma activity (Rook II, 1970).

The

effect of naproxen, administered alone and in combination with DBT
for 12 days, is shown in Figure 9.

As determined by a multifactorial

analysis of variance with the treatment variables DBT and naproxen,
there is no significant interactive effect with respect to PHA.

How-

ever, when the naproxen group is compared to the naproxen/DBT group
in a one-way analysis of variance, there is no significant difference
between them.

This suggests that DBT's fibrogenic properties are

modified in the presence of naproxen, but that the effects of this
antiinflammatory drug are moderate at best.

There is no significant

increase in serum alanine transaminase in any group.

The decrease

observed in the naproxen group is not meaningful on a physiological
level.
DBI-induced toxicity is similar in many respects to the clinical
entity, primary biliary cirrhosis (PBC).

PBC is a chronic liver

disease typified histologically by destructive cholangitis.

As such,

the term PBC is a misnomer but has been adhered to by convention.
PBC has been categorized as an autoimmune disease by virtue of
antiductular cell (Paronetto et al., 1964a and 1964b) and antimitochondrial (Dickson et al., 1979)

antibodies present in the liver.

However, an autoimmune etiology is by no means established.
The histological appearance of DBI-induced fibrosis, like PBC
(Rubin et al., 1965), begins with

p~riportal

inflammation and bile
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duct proliferation and progresses to destructive cholangitis and,
finally, to fibrosis in its later stages.

PHA is increased in PBC

prior to histologically demonstrable collagen accumulation (Jain
et al., 1978) as is seen in DBT-injured livers.

Impaired cell-mediated

immunity has been associated with PBC (MacSween and Thomas, 1973;
Schaffner, 1979) and is produced by the administration of DBT to
(Seinen et al., 1977a and 1977b).

rats

Finally, it has been suggested that

PBC is drug-induced since this disease is associated with a history
of drug hypersensitivity (Paronetto, 1964a).
The similarities between PBC and DBT-induced liver injury and
the immunologic alterations in the former raised the suspicion that
DBT's effects on the liver might have an immunologic component.
i~variable

The

failure of a small number of DBT-treated rats to respond

with the hepatic lesions typical of DBT exposure, also suggested a
host-dependent factor in DBT-induced injury.
Since DBT administration to neonatal rats impairs cell-mediated
immunity and produces thymus atrophy (Seinen et al., 1977a and 1977b)
and thymotoxic compounds are less effective in

adult animals, hepatic

injury produced by DBT was compared in various age groups.

This was

to serve as a starting point in the investigation of a possible relationahip between impaired thymus-dependent immunity and liver injury.
DBT administration for 12 days to rats 14 weeks of age at the start
of treatment produces periportal fibrosis similar to that described
above for rats 9 weeks of age.
relatively resistant.

However, the 4-week-old group is

In this latter group, PHA is elevated by 125%

of control as compared to 146% and 215%

in the 9 and 14 week-old
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groups, respectively (Table 4).

Leucocytosis (Table 5) and weight

loss (Figure 12), usually associated with DBT-induced liver injury,
are absent in these younger rats.

Liver histology in these 4-week-

old rats is similar to that seen in control animals (Figure 11).
The age-dependent effects of DBT strengthened the suspicion that
DBT-induced liver injury may have an immunologic component and, specifically, one that is thymus-dependent.

When thymus weights were

measured .in 4-week-old rats treated with DBT for 12 days (Table 6), it
became apparent that DBT produces thymotoxicity in these animals
similar to that reported in the literature for neonatal rats (Seinen
et al., 1977a and 1977b).

This thymus atrophy can not be attributed

to dehydration since the effect is equally pronounced expressed as wet
or dry weight.
To determine whether the inverse relationship between DBTinduced thymotoxicity and liver injury is related to a thymus-dependent
immunologic component in the latter, a number of immunologic studies
were performed on the 9-week-old rats.

The assay for lectin-dependent

lymphocyte-mediated cytolysis shows no difference between control and
DBT-treated rats indicating that cytotoxic lymphocytes are not associated with DBT-induced liver injury.
The test for delayed-type hypersensitivity (Table 7) shows a
characteristic foot swelling subsequent to a challenge dose of DBT
in both control rats and those administered DBT for 12 days.
suggests that an immunologic reaction is not responsible.

This

Histologi-

cal observation of feet from control and DBT-treated rats, both of
which were challenged with DBT, reveals no apparent differences.
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However, striking differences are observed in rats challenged with
DBT (Figure 12b) or DBT/liver compared to vehicle (Figure 12a) or
liver.

The predominantly polymorphonuclear cell infiltration in

Figure 12b is indicative of acute inflammation.
Since thymotoxicity could impair hum.oral immunity through thelper cells, direct immunofluorescence was used to look for the
presence of antibodies directed against DBT and/or hepatic antigens
in livers of DBT-treated rats.

The immunofluorescence observed was

localized to, but of uniform intensity throughout, portal tracts.
It is suggestive of a reaction against serum IgG, which is likely
to be increased periportally due to the inflammation.

The immuno-

fluorescence is not intensified at a given cell type or area within
the portal tract.
No evidence for immunologic processes in DBT-induced liver injury
is provided by these experiments.

However, one can only conclude

from these studies that an immunologic component of DBT-induced liver
injury is not apparent at this time.

If the duration of DBT exposure

in rats could be expanded to more closely approximate drug-induced
liver disease in humans, immunologic processes might become evident.
One must consider that the immunologic processes seen in association
with destructive cholangitis in human liver disease are usually
investigated in late stages of the disease.

This is due to both the

lack of availability of liver biopsies in early stages of human
liver disease for ethical reasons and the insidious onset of PBC
(Dickson et al., 1979).

Also, the immunologic phenomena are gener-

ally beleived to be reactive rather than eausative in destructive
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cholangitis (Popper and Schaffner, 1970) and, therefore, would be
expected to appear in more advanced stages of such liver disease.
Since the metabolic capabilities of the hepatic microsomal
monooxygenase system increase with maturity (Niems et al., 1976)
and DBT has been shown to be metabolized by this system in rats
(Kinnnel et al., 1977), the relationship of possible differences in
such metabolism to the age-dependent effects of DBT was investigated.

An inhibitor of hepatic microsomal enzymes, SKF 525A, was administered
alone and concomitantly with DBT for 4 days.

The effects of such

treatments on PHA and serum alanine transaminase are shown in Figure
13.

DBT-induced elevation of alanine transaminase is completely

inhibited by SKF 525A.
PHA is elevated in both the DBT and SKF 525A groups.

However,

PHA in the DBT/SKF 525A group is less than what would be expected
if the effect of these drugs on this enzyme are additive.

Indeed,

the interactive effect is significant as determined by a multifactorial
analysis of variance with the treatment variables DBT and SKF 525A.
This interaction is not likely to be a result of threshold prolyl
hydroxylase activation since higher levels (4-fold) have been
observed in experimental liver injury after 4 days of treatment with
dimethylnitrosamine (Ristelli et al., 1978).

The prolyl hydroxylase

values in DBT/SKF 525A-treated rats are not erroneously low due to
altered liver protein content since there is no .change in the latter
in any group.

There is a positive correlation between PHA and serum

alanine transaminase values in the control and DBT groups (r=+o.83).
However, the correlation between these two parameters in the control
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and SKF 525A groups is negative (r=-0.81).

This suggests that DBT-

induced PHA elevation is associated with parenchymal liver injury,
and that of SKF 525A is independent of such injury and caused at
least in part by a different mechanism.
Periportal inflammation and biliary injury, usually seen in
DBT-treated rats after 4 days (Figure 6b), are absent in livers from
rats that received SKF 525A in combination with DBT (Figure 16).
Livers from this group of animals differ from control only in the
presence of fatty infiltration.

Livers from SKF 525A-treated rats

are similar to those in the DBT/SKF 525A group; portal tracts show
no evidence of fibrosis despite elevated PHA (Figure 14), but fatty
infiltration is apparent throughout the parenchyma (Figure 15).
SKF 525A has been shown to inhibit microsomal drug metabolizing
enzymes (Niems et al., 1976), to prevent biliary excretion of xenobiotics through its effect on the metabolism of these compounds
(Levine et al., 1970), and to prevent gastrointestinal absorption
of certain drugs (McLean and Ma.rehang, 1970).

Therefore, each of

these effects must be considered as possible contributions to the
pharmacologic interaction between DBT and SKF 525A.
Microsomal oxidation of alkyltin compounds produces hydroxylated
metabolites, some of which are highly unstable and rapidly destannylated (Kimmel et al., 1977) and some of which retain their biological
activity (Aldridge et al., 1977).

In the case of tributyltin meta-

bolites, which have been extensively studied, one has been shown
to possess increased potency with respect to one of the parent
compound's toxic effects, but the remaining four identified meta-
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bolites are either highly unstable or decreased in biologic activity
(Aldridge et al., 1977).

The product of DBT destannylation,

~ono

butyltin, has been reported to be relatively devoid of toxic effects
(Barnes and Magos, 1968).

Thus, for microsomal metabolism to produce

an overall increase in liver toxicity, the more stable metabolites of
DBT would have to exhibit rather potent toxicity to compensate for
the relative inertness of monoalkyltin.

Since there is no evidence

that metabolism of tri- or dialkyltin compounds substantially increases
their toxicity, it is unlikely that the protective effect of SKF 525A
is due to decreased production of toxic metabolites.
Metabolism of DBT would be likely to increase the biliary excretion of this compound for two reasons.

Firstly, metabolites would

be likely to possess a more polar group thereby enhancing excretion
(Kimmel et al., 1977; Levine, 1978).

Secondly, microsomal metabolism

would probably result in metabolites of increased molecular weight
bringing the molecular weight of DBT (M.W. 304) above the approximate
lower threshold value of between 200-300 (Levine, 1978).

Thus, it

seems likely that inhibition of metabolism by SKF 525A could decrease
the biliary excretion of DBT and/or its metabolites.
Finally, SKF 525A has been reported to impair gastrointestinal
absorption of various drugs
is tempory, however.

(M~Lean

and Marchand, 1970).

This effect

After one hour (one hour after drug administra-

tion and 1.5 hours after SKF 525A administration), blood levels of
the drugs examined were actually significantly greater in SKF 525Atreated rats compared to controls.

With respect to DBT, 10 mg/kg/day,

p.o • .administered to rats has been shown to increase PHA significantly
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by

4 days time (Yermakoff, 1978).

Therefore, even if up to 50% of

the administered dose was not absorbed, an elevation of liver PHA
would still be anticipated in the presence of SKF 525A.

It does

not seem likely, therefore, that decreased gastrointestinal absorption of DBT by SKF 525A contributes substantially to the protective
effects of the latter.
In summary, the pharmacologic interaction between DBT and SKF 525A
may be due to multiple effects produced by SKF 525A including decreased
production of toxic metabolites, decreased biliary excretion of DBT
metabolites, and impaired gastrointestinal absorption of DBT.

How-

ever, available information suggests that impaired biliary excretion
via SKF 525A's inhibition of microsomal metabolism of DBT is likely
to contribute subbtantially to the protective effect.

Also, protection

against DBT-induced liver injury by this inhibitor via its effects on
microsomal metabolism may explain the age-related effects produced by
this organotin compound.

CONCLUSIONS

(1)

DBT administration from 0 to 4 days produces a gradual

increase in prolyl hydroxylase activity (PHA) and in vitro collagen
synthesis.

These two parameters are significantly correlated (r=0.94).

The biochemical changes are associated with the increasing appearance
of inflammatory cells and ductular cell proliferation and injury
during this same period.

(2)

At 4 days after DBT administration, serum alanine transamin-

ase is elevated approximately 4-fold.

This is probably a sequela to

the periportal inflammation since the hepatic injury observed at any
time during the course of DBT treatment is associated

wi~h

inflamma-

tion.

(3)

Twelve days of DBT treatment (20 mg/kg, q.o.d.) results in

increased PHA, increased protein synthesis directed toward collagen,
and an increase in hydroxyproline content.

These biochemical changes

are associated with histologically demonstrable periportal fibrosis.

(4)

Serum alanine transaminase and alkaline phosphatase activities

are not elevated after 12 days of DBT administration.

The return to

normal levels of serum alanine transaminase from the 4-fold increase
at 4 days time is not unusual since this enzyme generally peaks
early in the course of tissue injury.

Normal alkaline phosphatase

levels indicate that cholestasis is not a factor in DBT-induced liver
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injury at this time.

(5)

Histopathology after 12 days of DBT treatment reveals

extensive periportal inflammation and biliary injury in association
with fibrosis.

The contribution of inflammation to the development

of fibrosis is supported by the modification of DBT-induced PHA elevation by the nonsteroidal antiinflammatory drug, naproxen.

(6)
of DBT.

Rats 4 weeks of age are relatively resistant to the effects
In this 4-week-old group, PHA was 125% of control compared

to 146% and 215% in the 9 and 14 week groups, respectively.

Leuco-

cytosis and weight loss, usually associated with DBT-induced liver
injury, are absent in these younger rats.

(7)

A thymocyte-dependent immunologic component of DBT's

effects on the liver in the 9 and 14 week-old groups is suggested by
the relative resistance of these 4-week-old rats with thymus atrophy
to liver injury.

Investigation of lymphocyte-mediated cytolysis,

delayed-type hypersensitivity, and imnunofluorescence in DBT-treated
rats failed to reveal such an immunologic component.

(8)

The relationship of differences in hepatic microsomal

metabolism to the age-related effects of DBT was investigated using
SKF 525A.

There was a significant interaction with respect to the

effects of DBT and SKF 525A on PHA.

Administration of SKF 525A with

DBT completely inhibited the increase in serum alanine transaminase
seen with DBT alone after 4 days of treatment.

Periportal inflammation
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and biliary changes seen with DBT treatment alone were absent in these
rats.

Although the effects of SKF 525A may be due, in part, to the

absence of DBT metabolites with greater biologic activity or impaired
absorption of this organotin, they are more likely to involve decreased biliary excretion of the DBT and/or its metabolites.

The

interaction of SKF 525A with DBT suggests decreased biliary excretion
via metabolism as a factor in the age-dependent effects produced by
this organotin compound.
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